Historical record - last NADAC effective date: 10/19/2016

Product Information

MORPHINE SULFATE ER 30 MG CAP is a generic product labeled by Actavis Pharma, Inc., priced at $4.5987 per EA under NDC 00228309011. Its NADAC has been published 179 times since Jun 18, 2014.

FDA first approved this application on Jan 16, 2013.

The High Outlier badge above means this manufacturer's average price in the Morphine sulfate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

MORPHINE SULFATE ER 30 MG CAP

Morphine sulfate
$4.5987per EA
High Outlier
DEA Schedule CII

Strength

30 mg/1

NDC

00228309011

Classification

Generic

Dosage Form

CAPSULE, EXTENDED RELEASE

Route

ORAL

Effective Date

10/19/2016

Active Ingredients

MORPHINE SULFATE

Approval Type

Generic (ANDA)

FDA Application

ANDA079040

FDA Approved

1/16/2013

On Market Since

2/4/2014

Pharmacological Classes

Full Opioid Agonists
Opioid Agonist

Price Statistics

The NADAC for MORPHINE SULFATE ER 30 MG CAP has been published 179 times since Jun 18, 2014, and over the history we have for it it has declined 3.7%. The table below summarizes its recorded NADAC range and movement.

Current price$4.5987 per EA
All-time high$4.9125 (Nov 12, 2014)
All-time low$4.4021 (May 18, 2016)
Median price$4.6822
Average price$4.6632
Largest weekly change-9.2% (May 18, 2016)
Weeks tracked179
Tracking sinceJun 18, 2014

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

-3.7%

Last surveyed Nov 15, 2017 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Morphine sulfate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Frequently asked questions

What is the NADAC price of MORPHINE SULFATE ER 30 MG CAP?

The current National Average Drug Acquisition Cost (NADAC) for MORPHINE SULFATE ER 30 MG CAP, manufactured by Actavis Pharma, Inc., is $4.5987 per EA (NDC 00228309011), effective Nov 15, 2017.

How has the price of MORPHINE SULFATE ER 30 MG CAP changed over time?

Over the history we have for it, the NADAC for MORPHINE SULFATE ER 30 MG CAP has declined 3.7%. It has been tracked across 179 weekly CMS publications since Jun 18, 2014.

What are the highest and lowest recorded NADAC prices for MORPHINE SULFATE ER 30 MG CAP?

Since Jun 18, 2014, the NADAC for MORPHINE SULFATE ER 30 MG CAP has ranged from a low of $4.4021 (May 18, 2016) to a high of $4.9125 (Nov 12, 2014), with a median of $4.6822 per EA.

Are there cheaper alternatives to MORPHINE SULFATE ER 30 MG CAP?

No other NADAC-published product currently shares the active ingredient and strength of MORPHINE SULFATE ER 30 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures MORPHINE SULFATE ER 30 MG CAP?

MORPHINE SULFATE ER 30 MG CAP (NDC 00228309011) is labeled by Actavis Pharma, Inc., and CMS classifies it as a generic product.